| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Nicholas W Morrell | Q60960702 |
| P433 | issue | 8 | |
| P921 | main subject | pulmonary hypertension | Q1128595 |
| P304 | page(s) | 680-686 | |
| P577 | publication date | 2006-11-01 | |
| P1433 | published in | Proceedings of the American Thoracic Society | Q7247176 |
| P1476 | title | Pulmonary hypertension due to BMPR2 mutation: a new paradigm for tissue remodeling? | |
| P478 | volume | 3 |
| Q35062168 | A novel in vivo approach to assess radial and axial distensibility of large and intermediate pulmonary artery branches |
| Q37091591 | Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females |
| Q41689585 | Ataxia-Telangiectasia Mutated (ATM) Protein Signaling Participates in Development of Pulmonary Arterial Hypertension in Rats. |
| Q34483074 | BMP promotes motility and represses growth of smooth muscle cells by activation of tandem Wnt pathways |
| Q34293026 | BMP type II receptors have redundant roles in the regulation of hepatic hepcidin gene expression and iron metabolism |
| Q31047574 | BMP-9 induced endothelial cell tubule formation and inhibition of migration involves Smad1 driven endothelin-1 production |
| Q43834545 | BMPR-II is dispensable for formation of the limb skeleton |
| Q45881763 | BMPR2 gene delivery reduces mutation-related PAH and counteracts TGF-β-mediated pulmonary cell signalling |
| Q28569097 | Bone morphogenetic protein 4 enhances canonical transient receptor potential expression, store-operated Ca2+ entry, and basal [Ca2+]i in rat distal pulmonary arterial smooth muscle cells |
| Q42332006 | Clinical significance linked to functional defects in bone morphogenetic protein type 2 receptor, BMPR2. |
| Q35412283 | Combination use of sildenafil and simvastatin increases BMPR-II signal transduction in rats with monocrotaline-mediated pulmonary hypertension |
| Q39345470 | Critical effects of epigenetic regulation in pulmonary arterial hypertension |
| Q27005594 | DNA Damage and Pulmonary Hypertension |
| Q37252723 | Defective pulmonary vascular remodeling in Smad8 mutant mice |
| Q37677437 | Discerning functional hierarchies of microRNAs in pulmonary hypertension |
| Q42134956 | Downregulation of bone morphogenetic protein receptor axis during HIV-1 and cocaine-mediated pulmonary smooth muscle hyperplasia: implications for HIV-related pulmonary arterial hypertension |
| Q36761071 | Dysfunctional intracellular trafficking in the pathobiology of pulmonary arterial hypertension. |
| Q54425463 | Dysregulation of the IL-13 receptor system: a novel pathomechanism in pulmonary arterial hypertension. |
| Q33685088 | Early mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva |
| Q42442958 | Effects of bone morphogenic proteins and transforming growth factor-beta on In-vitro production of endothelin-1 by human pulmonary microvascular endothelial cells |
| Q48096975 | Endothelial-to-mesenchymal transition in cardiovascular diseases: Developmental signaling pathways gone awry |
| Q34357126 | Gene delivery of cytochrome p450 epoxygenase ameliorates monocrotaline-induced pulmonary artery hypertension in rats |
| Q39668321 | Genetic and pharmacological inhibition of retinoic acid receptor γ function promotes endochondral bone formation. |
| Q37080526 | Genetics of pulmonary arterial hypertension |
| Q36739882 | Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension |
| Q33915567 | Heritable forms of pulmonary arterial hypertension |
| Q40065596 | Hyperactive TGF-β Signaling in Smooth Muscle Cells Exposed to HIV-protein(s) and Cocaine: Role in Pulmonary Vasculopathy |
| Q26851508 | Immune and inflammatory mechanisms in pulmonary arterial hypertension |
| Q24658407 | Induction of microRNA-221 by platelet-derived growth factor signaling is critical for modulation of vascular smooth muscle phenotype |
| Q92189824 | Inflammation in pulmonary artery hypertension |
| Q38111730 | Inflammatory mechanisms in the pathogenesis of pulmonary arterial hypertension |
| Q92189114 | Joint Transcriptomic Analysis of Lung Cancer and Other Lung Diseases |
| Q37787547 | Key role of the RhoA/Rho kinase system in pulmonary hypertension |
| Q93204496 | Long non-coding RNAs influence the transcriptome in pulmonary arterial hypertension: the role of PAXIP1-AS1 |
| Q47449827 | Loss of SMAD3 Promotes Vascular Remodeling in Pulmonary Arterial Hypertension via MRTF Disinhibition |
| Q39673639 | Macrophage bone morphogenic protein receptor 2 depletion in idiopathic pulmonary fibrosis and Group III pulmonary hypertension |
| Q46181717 | Measuring outcomes in PAH: the gap between the measures that are used and their validity |
| Q47671193 | MicroRNA-424(322) as a new marker of disease progression in pulmonary arterial hypertension and its role in right ventricular hypertrophy by targeting SMURF1. |
| Q38676413 | Molecular pathogenesis and current pathology of pulmonary hypertension |
| Q36736065 | Molecular pathogenesis of pulmonary arterial hypertension |
| Q33702040 | Multikinase inhibitor sorafenib prevents pressure overload-induced left ventricular hypertrophy in rats by blocking the c-Raf/ERK1/2 signaling pathway |
| Q90649930 | Nanotherapeutics for Treatment of Pulmonary Arterial Hypertension |
| Q46183692 | Natural Antioxidants as Potential Therapy, and a Promising Role for Melatonin Against Pulmonary Hypertension |
| Q92920252 | New pathogenic variant of BMPR2 in pulmonary arterial hypertension |
| Q48140350 | Non-suppressive regulatory T cell subset expansion in pulmonary arterial hypertension |
| Q37066778 | Novel approaches to pulmonary arterial hypertension drug discovery |
| Q38310428 | Oxidative injury is a common consequence of BMPR2 mutations |
| Q28578858 | PGC1α-mediated mitofusin-2 deficiency in female rats and humans with pulmonary arterial hypertension |
| Q26821779 | Pathobiology of pulmonary arterial hypertension and right ventricular failure |
| Q36784800 | Pulmonary arterial hypertension: a disease of tethers, SNAREs and SNAPs? |
| Q37184405 | Pulmonary hypertension: therapeutic targets within the serotonin system. |
| Q49679389 | RV pressure overload: from hypertrophy to failure. |
| Q34467523 | Regulation of bone morphogenetic protein 9 (BMP9) by redox-dependent proteolysis. |
| Q37174962 | Rho-kinase inhibition alleviates pulmonary hypertension in transgenic mice expressing a dominant-negative type II bone morphogenetic protein receptor gene. |
| Q28941771 | SMAD proteins control DROSHA-mediated microRNA maturation |
| Q38112038 | Smooth muscle cell hypertrophy, proliferation, migration and apoptosis in pulmonary hypertension |
| Q43014041 | Smurf1 ubiquitin ligase causes downregulation of BMP receptors and is induced in monocrotaline and hypoxia models of pulmonary arterial hypertension |
| Q28275410 | TGFβ signalling in context |
| Q90250650 | Targeting epigenetic mechanisms as an emerging therapeutic strategy in pulmonary hypertension disease |
| Q57167791 | The Regulation of Pulmonary Vascular Tone by Neuropeptides and the Implications for Pulmonary Hypertension |
| Q98770789 | The Role and Regulation of Pulmonary Artery Smooth Muscle Cells in Pulmonary Hypertension |
| Q89941195 | The changing face of pulmonary hypertension diagnosis: a historical perspective on the influence of diagnostics and biomarkers |
| Q27027507 | The genetics of pulmonary arterial hypertension |
| Q39152712 | The lysosomal inhibitor, chloroquine, increases cell surface BMPR-II levels and restores BMP9 signalling in endothelial cells harbouring BMPR-II mutations |
| Q37147106 | Transdifferentiation of alveolar epithelial type II to type I cells is controlled by opposing TGF-β and BMP signaling |
| Q49471057 | Translational Advances in the Field of Pulmonary Hypertension. From Cancer Biology to New Pulmonary Arterial Hypertension Therapeutics. Targeting Cell Growth and Proliferation Signaling Hubs |
| Q35533520 | VIP and endothelin receptor antagonist: an effective combination against experimental pulmonary arterial hypertension |
| Q37778482 | Vascular development: genetic mechanisms and links to vascular disease |
| Q37778607 | Vascular remodeling in pulmonary arterial hypertension: Multiple cancer-like pathways and possible treatment modalities |
| Q98771780 | When Innate Immunity Meets Angiogenesis-The Role of Toll-Like Receptors in Endothelial Cells and Pulmonary Hypertension |
| Q28237461 | Whole-exome sequencing reveals TopBP1 as a novel gene in idiopathic pulmonary arterial hypertension |
Search more.